Appraising SARS-CoV-2 infections after full mRNA COVID-19 vaccination in patients with systemic lupus erythematosus (SLE)
The 2019 Coronavirus disease (COVID-19) vaccine is a major weapon in the fight against the severe acute respiratory syndrome brought about by coronavirus 2 (SARS-CoV-2). The vaccine significantly reduces the risk and severity of infection by SARS-CoV-2. Patients with systemic lupus erythematosus (SL...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-12-01
|
| Series: | Clinical Immunology Communications |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2772613422000087 |
| _version_ | 1811224595347275776 |
|---|---|
| author | Anderson Anuforo Michael Sandhu Jianghong Yu Andras Perl |
| author_facet | Anderson Anuforo Michael Sandhu Jianghong Yu Andras Perl |
| author_sort | Anderson Anuforo |
| collection | DOAJ |
| description | The 2019 Coronavirus disease (COVID-19) vaccine is a major weapon in the fight against the severe acute respiratory syndrome brought about by coronavirus 2 (SARS-CoV-2). The vaccine significantly reduces the risk and severity of infection by SARS-CoV-2. Patients with systemic lupus erythematosus (SLE) need protection from vaccine-preventable diseases including COVID-19. SLE patients have higher rates of severe infections due to immunosuppressive therapies and multiple immunologic defects – both of which are capable of blunting the immune responses after vaccination. In the management of COVID-19, recommendations have been developed to guide adjustments and/or continuation of immunosuppressive therapies for an effective immune response following vaccination with mRNA-based or viral vector-delivered vaccines. Monoclonal antibodies have also become available since December 2021. Here we present three cases of SLE patients who contracted COVID-19 after vaccination. One was managed in ambulatory settings and two required inpatient hospital admission. |
| first_indexed | 2024-04-12T08:51:42Z |
| format | Article |
| id | doaj.art-6b7108ad04c44b299975225956a2c715 |
| institution | Directory Open Access Journal |
| issn | 2772-6134 |
| language | English |
| last_indexed | 2024-04-12T08:51:42Z |
| publishDate | 2022-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Clinical Immunology Communications |
| spelling | doaj.art-6b7108ad04c44b299975225956a2c7152022-12-22T03:39:34ZengElsevierClinical Immunology Communications2772-61342022-12-0125456Appraising SARS-CoV-2 infections after full mRNA COVID-19 vaccination in patients with systemic lupus erythematosus (SLE)Anderson Anuforo0Michael Sandhu1Jianghong Yu2Andras Perl3Department of Medicine, SUNY Upstate Medical University, Syracuse, NY, United States; Corresponding authors.Department of Medicine, SUNY Upstate Medical University, Syracuse, NY, United StatesDepartment of Rheumatology, SUNY Upstate Medical University, Syracuse, NY, United StatesDepartment of Rheumatology, SUNY Upstate Medical University, Syracuse, NY, United States; Corresponding authors.The 2019 Coronavirus disease (COVID-19) vaccine is a major weapon in the fight against the severe acute respiratory syndrome brought about by coronavirus 2 (SARS-CoV-2). The vaccine significantly reduces the risk and severity of infection by SARS-CoV-2. Patients with systemic lupus erythematosus (SLE) need protection from vaccine-preventable diseases including COVID-19. SLE patients have higher rates of severe infections due to immunosuppressive therapies and multiple immunologic defects – both of which are capable of blunting the immune responses after vaccination. In the management of COVID-19, recommendations have been developed to guide adjustments and/or continuation of immunosuppressive therapies for an effective immune response following vaccination with mRNA-based or viral vector-delivered vaccines. Monoclonal antibodies have also become available since December 2021. Here we present three cases of SLE patients who contracted COVID-19 after vaccination. One was managed in ambulatory settings and two required inpatient hospital admission.http://www.sciencedirect.com/science/article/pii/S2772613422000087 |
| spellingShingle | Anderson Anuforo Michael Sandhu Jianghong Yu Andras Perl Appraising SARS-CoV-2 infections after full mRNA COVID-19 vaccination in patients with systemic lupus erythematosus (SLE) Clinical Immunology Communications |
| title | Appraising SARS-CoV-2 infections after full mRNA COVID-19 vaccination in patients with systemic lupus erythematosus (SLE) |
| title_full | Appraising SARS-CoV-2 infections after full mRNA COVID-19 vaccination in patients with systemic lupus erythematosus (SLE) |
| title_fullStr | Appraising SARS-CoV-2 infections after full mRNA COVID-19 vaccination in patients with systemic lupus erythematosus (SLE) |
| title_full_unstemmed | Appraising SARS-CoV-2 infections after full mRNA COVID-19 vaccination in patients with systemic lupus erythematosus (SLE) |
| title_short | Appraising SARS-CoV-2 infections after full mRNA COVID-19 vaccination in patients with systemic lupus erythematosus (SLE) |
| title_sort | appraising sars cov 2 infections after full mrna covid 19 vaccination in patients with systemic lupus erythematosus sle |
| url | http://www.sciencedirect.com/science/article/pii/S2772613422000087 |
| work_keys_str_mv | AT andersonanuforo appraisingsarscov2infectionsafterfullmrnacovid19vaccinationinpatientswithsystemiclupuserythematosussle AT michaelsandhu appraisingsarscov2infectionsafterfullmrnacovid19vaccinationinpatientswithsystemiclupuserythematosussle AT jianghongyu appraisingsarscov2infectionsafterfullmrnacovid19vaccinationinpatientswithsystemiclupuserythematosussle AT andrasperl appraisingsarscov2infectionsafterfullmrnacovid19vaccinationinpatientswithsystemiclupuserythematosussle |